NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Repligen Corporation 

41 Seyon Street, Building #1, Suite 100

Waltham  Massachusetts  02495  U.S.A.
Phone: 781-250-0111 Fax: 781-250-0115


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Repligen Corporation (RGEN) Announces Conference Call of Second Quarter Fiscal Year 2010 Results Thursday, November 5th, 10:00 a.m. EST 10/29/2009 10:46:59 AM    More...
Repligen Corporation (RGEN) Licenses Potential Treatment for Spinal Muscular Atrophy; Conference Call Scheduled for Friday, October 23 at 8:30 a.m. EDT 10/23/2009 9:04:27 AM    More...
Repligen Corporation (RGEN) Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas 10/19/2009 11:28:48 AM    More...
Repligen Corporation (RGEN) Announces Identification of Drug Target for Friedreich's Ataxia Study Published in the September 25, 2009 Issue of Chemistry & Biology 9/25/2009 7:33:22 AM    More...
Repligen Corporation (RGEN) to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT 9/2/2009 9:04:40 AM    More...
Repligen Corporation (RGEN) Announces Conference Call of First Quarter Fiscal Year 2010 Results 7/30/2009 9:08:24 AM    More...
Repligen Corporation (RGEN) Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6/11/2009 11:20:36 AM    More...
Repligen Corporation (RGEN) Licenses Patent Rights for Treatment of Bipolar Disorder 3/31/2009 10:47:33 AM    More...
Repligen Corporation (RGEN) Announces ISO 9001:2000 Certification 2/12/2009 6:43:54 AM    More...
Repligen Corporation (RGEN) Reports Third Quarter Fiscal Year 2009 Financial Results 2/5/2009 10:00:19 AM    More...
12345678910...